Kura Oncology, Inc. KURA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
46/100
Developing

Ranked against 712 peers in Biotechnology

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent … Full KURA analysis →

Key strengths

  • Cash Generation Consistent Cash generation is consistent (score 0.71), indicating reliable business model.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.71).

Key risks

  • ROIC Below WACC or Peers ROIC at 24.0th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.27), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
30
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where KURA ranks in Biotechnology

Kura Oncology, Inc. ranks #293 of 713 scored companies in Biotechnology by moat score — the top 41%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
289 XBiotech Inc. XBIT 46/100 Developing
290 KalVista Pharmaceuticals, Inc. KALV 46/100 Developing
291 Mind Medicine (MindMed) Inc. MNMD 46/100 Developing
292 Amylyx Pharmaceuticals, Inc. AMLX 46/100 Developing
293 Kura Oncology, Inc. KURA 46/100 Developing
294 Vivani Medical, Inc. VANI 45/100 Developing
295 Relay Therapeutics, Inc. RLAY 45/100 Developing
296 Revance Therapeutics, Inc. RVNC 45/100 Developing
297 Autolus Therapeutics plc AUTL 45/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How KURA scores on the Corporate Default defenses

Pricing Power

Score 30 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 53 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 71 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 31 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 46 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 59 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding KURA's moat

What is Kura Oncology, Inc.'s moat score?

Kura Oncology, Inc. (KURA) scores 46 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #293 of 713 scored companies in Biotechnology, the top 41%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (71/100) and its weakest is Pricing Power (30/100).

How does Kura Oncology, Inc. compare with other Biotechnology companies?

Kura Oncology, Inc. ranks #293 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Amylyx Pharmaceuticals, Inc. (AMLX) at 46 just above it and Vivani Medical, Inc. (VANI) at 45 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Kura Oncology, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Kura Oncology, Inc.?

The Corporate Default template measures 6 defenses, and KURA scores: Pricing Power (30), Cost Advantage (53), Customer Stickiness (71), Capital Efficiency (31), Resilience (46), Scale & Market Position (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000